Children HIV-exposed and uninfected (CHEU) in rural Zimbabwe had 40% higher mortality than children who were HIV-unexposed. HIV transmission rates exceeded elimination targets, and half of CHEU were stunted by 18 months of age, highlighting ongoing disparities in clinical outcomes.
INTRODUCTION
Before the availability of prevention-of-mother-to-child transmission (PMTCT) interventions in sub-Saharan Africa, HIV was a major contributor to child mortality. In a Zimbabwean birth cohort between 1997-2001, 80% of all child deaths were among HIV-exposed children. 1 Overall mother-tochild HIV transmission was 27%, but even children who were HIV-exposed but uninfected (CHEU) had 3-fold higher mortality than children who were HIV-unexposed (CHU), 1 and poor growth was common. 2, 3 Similar findings were reported from several sub-Saharan African settings. 4 An estimated 1.4 million children are born to women living with HIV annually. 5 The increasing availability of antiretroviral therapy (ART) in sub-Saharan Africa now means the vast majority of these children avoid HIV tranmission; 5, 6 however, the outcomes of children exposed to HIV are poorly described. Since the global goal is to ensure that all children survive, thrive and lead transformative lives, 7 it is important to know how well PMTCT programmes are reducing HIV transmission, and whether health and growth of CHEU have normalised. We therefore compared clinical outcomes between children who were HIV-exposed and HIV-unexposed in rural Zimbabwe. 
METHODS

SHINE trial
The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial 8 recruited pregnant women from two rural Zimbabwean districts with 15% antenatal HIV prevalence, between November 2012 and March 2015. SHINE was a 2x2 factorial cluster-randomised trial assessing the effects of improved infant and young child feeding (IYCF) and improved water, sanitation and hygiene (WASH) on stunting and anaemia at 18 months of age. Mother-infant pairs lived in clusters randomised to standard-of-care (SOC); IYCF (20g small-quantity lipid-based nutrient supplement/day from 6-18 months of age, and complementary feeding counselling); WASH (pit latrine and 2 hand-washing stations, liquid soap and chlorine, a clean play space, and hygiene counselling); or IYCF+WASH (all interventions). Results were stratified by maternal HIV status, and have been reported. [9] [10] [11] [12] 
Data collection
Research nurses visited mothers in early pregnancy (~2 weeks after consent) and at 32 gestational weeks, to assess maternal and household characteristics. At baseline, mothers had height, weight, mid-upper arm circumference (MUAC) measured, and household wealth assessed. 13 Infant birth date, weight, and delivery details were transcribed from health records. Home visits were scheduled at 1, 3, 6, 12, and 18 months postpartum. Infant weight, length and MUAC were measured at every visit, and head circumference from 3 months of age. Nurses were standardised on anthropometric measurement every 6 months. Breastfeeding exclusivity was assessed at the 1-, 3-, and 6-month visits; continued breastfeeding was assessed at 12 and 18 months. Mortality was assessed through home visits, village health worker reports and telephone calls, with date of death recorded where available. Maternal ART was documented at three timepoints (baseline, 32 gestational weeks and 1month postpartum) based on maternal report and review of handheld medical records. and were referred to local clinics. Viral loads were not measured. National PMTCT guidelines changed from WHO Option B (maternal ART from 14 gestational weeks until the end of breastfeeding) to Option B+ (lifelong ART for all pregnant and breastfeeding women) in November 2013. Women were encouraged to initiate co-trimoxazole and ART, to exclusively breastfeed, and to attend clinic at 6 weeks postpartum for early infant diagnosis and co-trimoxazole. The first-line ART regimen in Zimbabwe was two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI); the second-line regimen was two NRTIs and a protease inhibitor. Women testing HIV-negative in pregnancy were offered re-testing at 18 months postpartum to detect seroconversion.
HIV testing
HIV-positive mothers were invited to enroll in a substudy in which children had blood collected at 1, 3, 6, 12 and 18 months for HIV testing; children of mothers not enrolling were only tested at 18 months. Children testing positive were referred to local clinics for ART. Children testing HIV-negative at 18 months were classified as HIV-exposed uninfected. Children not tested at 18 months due to caregiver refusal, defaulted visits, or loss to follow-up, were classified as HIV-unknown. Children who died were classified based on their HIV test result at the last trial visit before death, or as HIVunknown if they had never been tested or were not tested on the last trial visit before death. Before 18 months of age, HIV was diagnosed using DNA PCR on dried blood-spot samples or RNA PCR on plasma; and after 18 months, by PCR or rapid test algorithm, depending on samples provided. Inconclusive or discordant results were re-tested to confirm status; if no further samples were available or repeat testing was inconclusive, children were classified as HIV-unknown.
Statistical analyses
We compared baseline characteristics between groups using multinomial and ordinal regression models with robust variance estimation, and Somers' D for medians. We compared mortality 7 between HIV-exposed and HIV-unexposed groups using Cox proportional hazards models with robust variance estimation to account for clusters, adjusted for trial arm. When the exact date of infant death was unknown (11/249; 4%), an estimated date was assigned using the conditional median among children who died beyond the time-point when the child was last reported alive. To compare growth between CHEU and CHU, we used generalised estimating equations with an exchangeable working correlation structure, adjusted for trial arm. A log-binomial specification was used to estimate relative risks (RR). For our primary growth analysis, we did not adjust for other baseline covariates, because our aim was to evaluate whether there were differences between CHEU and CHU regardless of whether these were driven by biological, socioeconomic or demographic factors. As a secondary analysis, we adjusted for maternal and household baseline characteristics associated with the exposure (HIV exposure status) and outcomes (Z-scores) to determine if this had an effect on inferences. All analyses used Stata version 15.1 (StataCorp, TX, USA).
There was no effect of IYCF or WASH on mortality, 9, 10 therefore all children were included in mortality comparisons. Since IYCF improved growth and WASH had no effect, 9,10 children randomised to IYCF were excluded from growth analyses. Subgroup analyses were planned if there was a significant interaction between sex and HIV exposure. We undertook sensitivity analyses to estimate the proportion of HIV-unknown children likely to be infected, using a range of transmission scenarios.
Study oversight and registration
Mothers provided written informed consent. The Medical Research Council of Zimbabwe and Johns
Hopkins Bloomberg School of Public Health approved the study protocol. The trial is registered at ClinicalTrials.gov (NCT01824940).
RESULTS
Among 5280 pregnant women, there were 738 live births to 726 HIV-positive mothers and 3989 live births to 3937 HIV-negative mothers ( Supplementary Fig 1) . Baseline characteristics of mothers, households and children are shown in Table 1 . HIV-positive compared to HIV-negative mothers were on average 4 years older, spent fewer years at school, came from slightly smaller households and were in lower household wealth quintiles; their infants had lower birthweight and institutional delivery rates. Among the 726 HIV-positive mothers, 402 (55%) had documented co-trimoxazole use during pregnancy and 587 (81%) had documented ART use; of these, approximately two-thirds were receiving tenofovir-based regimens. Only two mothers received protease inhibitors. Mean (SD) CD4 count was 474 (221) cells/L; only 8% had CD4 counts <200 cells/L. Exclusive breastfeeding between birth and 6 months was high 14 and did not differ by HIV exposure (data not shown).
However, total duration of breastfeeding was shorter among HIV-positive compared to HIV-negative mothers (mean (SD) 14.8 (3.7) versus 16.4 (3.1) months).
Child mortality
Among 738 children exposed to HIV, 51 (7%; 95%CI 5, 9) died compared to 198 (5%; 95%CI 4, 6) of 3989 children who were HIV-unexposed (hazard ratio (HR) 1.41; 95%CI 1.02, 1.93) ( Figure 1 ). Of the 51 deaths in children exposed to HIV, 29 (57%) occurred before 28 days of age, 13 (25%) between 28 days and 6 months, 4 (8%) between 6 and 12 months, and 5 (10%) after 12 months. Of the 198 deaths in children who were HIV-unexposed, 122 (62%) occurred before 28 days, 37 (19%) between 28 days and 6 months, 27 (14%) between 6 and 12 months, and 12 (6%) after 12 months. Child sex did not modify the effects of HIV-exposure on mortality (P=0.57).
Of the 51 deaths in children exposed to HIV, 46 (90%) occurred among children with unknown HIV status; 45/46 died without any HIV testing, and one child was HIV-negative at the 1-month visit but died aged 6 months without further testing. Of the five children with known HIV status prior to death, three were HIV-positive and two were HIV-negative. Mortality was lower in children whose mothers received ART compared to those whose mothers did not receive ART in pregnancy (33/597 (6%) versus 18/141 (13%), respectively; HR 0.41, 95%CI 0.22, 0.76). Overall mortality among ARTexposed children was similar to children who were HIV-unexposed (HR 1.11, 95%CI 0.75, 1.65). By contrast, mortality among ART-unexposed children was almost 3-fold higher than among children who were HIV-unexposed (HR 2.74, 95%CI 1.69, 4.44).
Mother-to-child transmission of HIV
Among 738 children exposed to HIV, 25 (3%) were HIV-positive, 596 (81%) were CHEU, and 117 (16%) had an unknown status at 18 months. Mother-to-child transmission was therefore 4% (25/621) among those with known HIV status. Baseline characteristics of CHEU and HIV-positive infants and their mothers are shown in Supplementary Table 1 . HIV transmission by 18 months was 8 percentage points (95%CI 2, 15) lower in ART-exposed compared to ART-unexposed children (14/521 (3%) versus 11/100 (11%), respectively; RR 0.26, 95%CI 0.10, 0.63). To bound our estimates of HIV transmission in the whole cohort we undertook a sensitivity analysis, assuming various scenarios for HIV prevalence among the 117 children with unknown HIV status, which showed overall estimated HIV transmission of 4.3-7.7% (Supplementary Table 2 ).
Among 3937 women testing HIV-negative during pregnancy, 3387 (86%) were re-tested at 18 months postpartum; 41/3387 (1.2%, 95%CI 0.9, 1.6) had seroconverted during the postpartum period, meaning the 43 children born to these mothers became HIV-exposed during breastfeeding.
Of these 43 children, nine (21%) tested HIV-positive, 32 (74%) tested HIV-negative and two (5%) had an unknown HIV status at 18 months.
Child growth
Among 594 children exposed to HIV who were confirmed as CHEU at 18 months, 297 (50%) did not receive the IYCF intervention and were included in growth analyses. Among 3686 CHU assessed at 10 18 months, 1771 (48%) did not receive the IYCF intervention and were included in growth analyses ( Table 3 ).
Growth outcomes among HIV-positive children assessed at 18 months are shown in Supplementary   Table 4 .
To understand the timing and pattern of growth impairment, we assessed longitudinal anthropometry in children with available data at 1, 3, 6 and 12 months of age (Figure 2 and Supplementary Table 5 ). Growth failure began early: differences in length-for-age and weight-forage between CHEU and CHU were already apparent by 1 month of age. Weight-for-length in both groups was similar to WHO standards between 1 and 18 months and wasting was uncommon.
Differences in head circumference between groups were apparent at every time-point.
Alive, HIV-free and non-stunted
DISCUSSION
Although increased PMTCT coverage in sub-Saharan Africa has substantially reduced the number of children living with HIV, mortality and growth outcomes among children exposed to HIV remain uncertain. Our study in rural Zimbabwe has three key findings. First, despite >80% PMTCT coverage, mortality in children exposed to HIV remains 40% higher than in children not exposed to HIV, and occurs soon after birth; second, the proportion of children with HIV-positive or HIV-unknown status at 18 months remained above paediatric HIV elimination targets; and, third, growth of CHEU was significantly poorer than CHU, with more than half becoming stunted by 18 months. These findings from a rural setting with high antenatal HIV prevalence, similar ART coverage to global estimates 5 and high exclusive 14 and prolonged breastfeeding rates, highlight the urgent action that is needed to ensure that children born to HIV-positive mothers survive and thrive.
Overall, 5% of children died by 18 months. Mortality was predominantly early, with half of all deaths occurring in the first 9 days after birth. We found 40% increased mortality among children born to HIV-positive compared to HIV-negative mothers. Strikingly, 90% of HIV-exposed children who died had no HIV testing, because deaths mostly occurred before early infant diagnosis at 4-6 weeks of age. We were therefore unable to ascertain whether the excess mortality was due to HIV transmission, or whether CHEU have a higher risk of death. The 3-fold higher mortality among children exposed to HIV whose mothers did not receive ART was similar to findings in pre-ART Zimbabwe. 1 By contrast, children exposed to HIV whose mothers were receiving ART had similar mortality to HIV-unexposed children. Maternal ART, as well as reducing HIV transmission, may also benefit CHEU through decreased exposure to maternal viraemia, immunosuppression and inflammation 15, 16 . Regardless of whether antenatal ART reduces mortality directly by reducing HIV transmission or indirectly through other mechanisms, these findings reinforce the importance of ensuring that all HIV-positive pregnant women receive ART.
Among children with known HIV status at 18 months, mother-to-child transmission was 4%. Despite PMTCT availability, one-fifth of HIV-positive women had no evidence of ART use during pregnancy; among these women, MTCT was 11%. A worrying finding is that 16% of children had an unknown HIV status, even in the context of a clinical trial where longitudinal HIV testing was offered; this proportion is likely even higher in programmatic settings. 5 We therefore believe the 4% transmission rate is an underestimate, since untested children may have a higher transmission risk. Our sensitivity analysis estimated MTCT to be 4.3%-7.7% by 18 months; we suspect the true transmission rate lies towards the upper end of these estimates, highlighting the considerable work that is still needed to prevent fall-out from the PMTCT cascade. Another alarming finding is ongoing high HIV incidence among breastfeeding women, and the high MTCT rate (21%) among these mother-infant pairs, which is similar to estimates in Zimbabwe between 1997-2001. 18 Our collective findings argue strongly for additional interventions to improve infant outcomes. Antenatal and postnatal ART adherence support, more effective virological suppression during pregnancy and breastfeeding, HIV testing before 4-6 weeks of age, and enhanced infant post-exposure prophylaxis, may all be beneficial.
Despite avoiding HIV infection, half of all CHEU were stunted at 18 months of age. Stunting is associated with increased child mortality, reduced academic outcomes and lifelong earnings, and intergenerational effects on health and human capital. [19] [20] [21] [22] In areas of high HIV prevalence, this burden of stunting among CHEU therefore has enormous population impact. CHEU had 60% relative increase in severe stunting (LAZ<-3), which is concerning because the association between LAZ and mortality rises exponentially as LAZ falls. 22 Overall, growth impairment occurred early, with little recovery thereafter. CHEU had lower birthweight than CHU, and length was significantly lower when first measured at 1 month of age, consistent with an intrauterine effect of HIV exposure on ponderal and linear growth. Our linear growth findings are consistent with several other large cohorts in sub-Saharan Africa. [23] [24] [25] [26] CHEU also had reduced weight-for-age, MUAC and head circumference, highlighting the multiple anthropometric deficits that occur in this vulnerable group. Differences in head circumference may be particularly important, given our recent finding of poorer neurodevelopment at 2 years of age in CHEU from this same cohort. 27 The global ambition that all children should survive, thrive and lead transformative lives 7 is therefore particularly challenging in areas of high antenatal HIV prevalence. To focus efforts on this goal, we propose that PMTCT programmes should strive for the composite outcome of 'Alive, HIV-free and thriving' as an indicator of success, rather than HIV-free survival alone. Only 40% of children exposed to HIV were known to be alive, HIV-free and non-stunted at 18 months, compared to 60% of CHU.
This provides clear evidence that most CHEU are not reaching their full potential. Our recent finding, from this same cohort, that CHEU were particularly responsive to improved feeding, 10 provides optimism that children are amenable to interventions, despite their vulnerability. 28 This study has strengths and limitations. This is one of the largest comparisons of CHEU and CHU, with both groups drawn from the same rural communities. We restricted growth analyses to children not receiving the trial IYCF intervention. The population was well-characterised, had high rates of follow-up at 18 months, and underwent longitudinal HIV testing, thereby reducing bias from attrition and HIV misclassification. However, we were unable to determine HIV status among a substantial proportion of children, including most of those who died, meaning the overall HIV transmission rate was uncertain. The trial did not provide HIV care or dispense ART, but we encouraged attendance at local clinics, where PMTCT coverage was high, but not universal. We promoted exclusive breastfeeding to high levels 14 which may have reduced HIV transmission and improved health outcomes.
In summary, our study confirms a substantial ongoing impact of maternal HIV on child health in sub-Saharan Africa. Despite increasing availability of ART, mortality remains 40% higher among children exposed to HIV, mother-to-child transmission rates are above elimination targets, and half of CHEU are stunted. We propose the composite outcome of "Alive, HIV-free and thriving" as the long-term goal, with indicators such as stunting prevalence used to monitor PMTCT programmes. Our findings highlight the ongoing disparity between CHEU and CHU, and the need for additional interventions to ensure that all children survive and thrive.
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